[Clinico-pharmacological aspects of endogenous physiologically active compounds].
M D
MD
Mashkovskiĭ
D000818:Animals; D001685:Biological Factors / Q000494:pharmacology / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D057487:Enzyme Therapy; D005260:Female; D006728:Hormones / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology / Q000627:therapeutic use; D007372:Interferons / Q000494:pharmacology / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000494:pharmacology / Q000627:therapeutic use; D011247:Pregnancy; D011453:Prostaglandins / Q000494:pharmacology / Q000627:therapeutic use; D011941:Receptors, Adrenergic / Q000187:drug effects / Q000502:physiology; D011950:Receptors, Cholinergic / Q000187:drug effects / Q000502:physiology; D017981:Receptors, Neurotransmitter / Q000502:physiology*
D001685:Biological Factors; D004791:Enzyme Inhibitors; D006728:Hormones; D007166:Immunosuppressive Agents; D018377:Neurotransmitter Agents; D011453:Prostaglandins; D011941:Receptors, Adrenergic; D011950:Receptors, Cholinergic; D017981:Receptors, Neurotransmitter; D007372:Interferons
Farmakologo-klinicheskie aspekty ucheniia ob éndogennykh fiziologicheski aktivnykh soedineniiakh.